VECTAB
LIVE

Serial Number

79352355

Owner

VectorY B.V.

Attorney

Douglas T. Johnson

Filing Date

Aug 1, 2022

Add to watchlist:

No watchlists yet
View on USPTO

VECTAB Trademark

Serial Number: 79352355 • Registration: 7349426

VECTAB is a trademark filed by VectorY B.V. on August 1, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

VectorY B.V. (8 trademarks)

Science Park 408

Entity Type: 26

Trademark Details

Filing Date

August 1, 2022

Registration Date

April 9, 2024

Published for Opposition

January 23, 2024

Goods & Services

Viral systems comprised of viral vectors combined with antibodies; gene therapy systems comprised of viral vectors combined with antibodies; nucleic acid delivery systems being therapeutic agents for delivery to human tissue namely viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for the treatment neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; clinical medical reagents for use in nucleic acid-based therapy, cell therapy, pharmaceutical preparations, prophylaxis products preparations and other pharmaceutical products preparations and other pharmaceutical products preparations for use in nucleic acid-based therapy, gene therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases

Medical treatment by gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; consultancy in the field of pharmaceutics

Scientific and medical research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; Scientific and medical research and product development in the field of pharmaceutics

Filing History

FINAL DISPOSITION NOTICE SENT TO IB
Jan 1, 2025 FICS
FINAL DISPOSITION PROCESSED
Jan 1, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 19, 2024 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 9, 2024 R.PR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 9, 2024 NRCC
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 1, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 13, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 13, 2024 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 23, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 23, 2024 PUBO
NOTIFICATION PROCESSED BY IB
Jan 22, 2024 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 3, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 3, 2024 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 3, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 18, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 12, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 12, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 12, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 12, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 8, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 7, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 7, 2023 TROA
REFUSAL PROCESSED BY IB
Jul 22, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 27, 2023 RFCS
REFUSAL PROCESSED BY MPU
Jun 27, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 20, 2023 RFCR
NON-FINAL ACTION WRITTEN
May 19, 2023 CNRT
ASSIGNED TO EXAMINER
May 18, 2023 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Apr 11, 2023 NREP
APPLICATION FILING RECEIPT MAILED
Oct 18, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 14, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 13, 2022 REPR